Comparative Pharmacology
Head-to-head clinical analysis: PARAFLEX versus REVONTO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARAFLEX versus REVONTO.
PARAFLEX vs REVONTO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Centrally acting muscle relaxant; inhibits polysynaptic reflexes at the spinal cord level, possibly by depressing the central nervous system.
Remimazolam is a benzodiazepine that acts as a positive allosteric modulator of GABA-A receptors, enhancing the effects of GABA to produce sedation and anxiolysis.
250-500 mg orally once daily, may increase to 500 mg twice daily if needed. Maximum 500 mg/day.
4 mg orally twice daily, with or without food.
None Documented
None Documented
Terminal elimination half-life is approximately 2–3 hours, allowing for multiple daily dosing.
Terminal elimination half-life is approximately 18–20 hours in healthy adults, allowing once-daily dosing.
Renal excretion of unchanged drug and metabolites accounts for approximately 50% of an oral dose; fecal excretion accounts for about 20%.
Renal excretion of unchanged drug accounts for <1% of the dose; fecal excretion via biliary elimination is the primary route (≈90%), with the remainder as metabolites.
Category C
Category C
Skeletal Muscle Relaxant
Skeletal Muscle Relaxant